07:53 AM EDT, 09/18/2024 (MT Newswires) -- Immunic ( IMUX ) said Wednesday that interim data from a phase 2 trial show the potential effectiveness of its experimental drug vidofludimus calcium in progressive multiple sclerosis.

The company said the investigational drug was found to reduce neurofilament light chain levels compared with placebo in the study.

The company also said antiviral data suggested that the drug may reduce fatigue while preclinical data indicated that vidofludimus calcium promotes neuronal survival through the activation of nuclear receptor related 1, or Nurr1, and pathogenic T cell data support the drug's anti-inflammatory effects.

The data will be presented this week at a conference in Copenhagen, Denmark, Immunic ( IMUX ) said.